3 Neil Woodford High-Yield Shares: GlaxoSmithKline plc, Centrica PLC and SSE PLC

GlaxoSmithKline plc (LON:GSK), Centrica PLC (LON:CNA) and SSE PLC (LON:SSE) are three of the master investor’s high-income picks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskRenowned fund manager Neil Woodford has been thrashing the market for a quarter of a century. Woodford is a very selective stockpicker. Fewer than 1 in 10 of the UK’s top 350 companies earn a place in his funds.

Hence, I always keep an eye on his holdings for promising investment ideas.

The following three FTSE 100 firms all currently offer prospective dividend yields of above 5.5%, compared with the FTSE 100 average of 3.3%:

  Recent share price Forecast yield
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) 1,417p 5.6%
Centrica (LSE: CNA) (NASDAQOTH: CPYYY) 307p 5.7%
SSE (LSE: SSE) 1,438 6.2%

GlaxoSmithKline

GSK’s shares are trading close to a 52-week low. Allegations of bribery in China, which have hurt sentiment, were already in the public domain when Woodford loaded up on GSK stock for his new fund towards the end of June.

However, the UK’s top pharma company has since released disappointing half-year results, with competition from generic drugs, some supply-chain problems and adverse currency movements all playing a part. Core earnings are now expected to be flat for the full year (at constant exchange rates).

Nevertheless, management said “we remain confident in GSK’s medium and long-term growth prospects”. The Board lifted the Q2 dividend (the ex-dividend date is 6 August) by 6%, and analysts’ full-year expectations give a prospective yield of 5.6%.

Centrica

Just as GSK’s China troubles didn’t stop Woodford from investing in the pharma firm, so the political and regulatory headwinds currently buffeting the UK’s energy utilities didn’t stop him backing Centrica, the owner of British Gas. As with GSK, Centrica’s shares are currently trading close to a 52-week low.

Also like GSK, Centrica has recently released disappointing first-half results. Abnormal weather conditions played a big part, and management said full-year earnings will be lower than last year.

However, the company expects a return to growth in 2015 and the Board reaffirmed its “commitment to real dividend growth”. The half-year payout was lifted 4% (ex-dividend date of 24 September), and analysts’ full-year forecasts give a prospective yield of 5.7%.

SSE

SSE faces the same challenging political and regulatory environment as Centrica. But again, Woodford has backed the previously named Scottish & Southern Energy for his new fund.

SSE told shareholders at its AGM last month that despite tough energy market conditions, “we are on course to give shareholders a return on their investment through a dividend increase that at least keeps pace with inflation”.

Analysts are forecasting a rise of 3% or so on last year’s payout, which gives a prospective top-of-the-tree yield of 6.2%.

G A Chester has no position in any shares mentioned. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Could these 3 FTSE 100 shares soar in 2026?

Our writer identifies a trio of FTSE 100 shares he thinks might potentially have more petrol in the tank as…

Read more »

Pakistani multi generation family sitting around a table in a garden in Middlesbourgh, North East of England.
Dividend Shares

How much do you need in a FTSE 250 dividend portfolio to make £14.2k of annual income?

Jon Smith explains three main factors that go into building a strong FTSE 250 dividend portfolio to help income investors…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

275 times earnings! Am I the only person who thinks Tesla’s stock price is over-inflated?

Using conventional measures, James Beard reckons the Tesla stock price is expensive. Here, he considers why so many people appear…

Read more »

Investing Articles

Here’s what I think investors in Nvidia stock can look forward to in 2026

Nvidia stock has delivered solid returns for investors in 2025. But it could head even higher in 2026, driven by…

Read more »

Investing Articles

Here are my top US stocks to consider buying in 2026

The US remains the most popular market for investors looking for stocks to buy. In a crowded market, where does…

Read more »

Investing Articles

£20,000 in excess savings? Here’s how to try and turn that into a second income in 2026

Stephen Wright outlines an opportunity for investors with £20,000 in excess cash to target a £1,450 a year second income…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Is a 9% yield from one of the UK’s most reliable dividend shares too good to be true?

Taylor Wimpey’s recent dividend record has been outstanding, but investors thinking of buying shares need to take a careful look…

Read more »

Snowing on Jubilee Gardens in London at dusk
Value Shares

Is it time to consider buying this FTSE 250 Christmas turkey?

With its share price falling by more than half since December 2024, James Beard considers the prospects for the worst-performing…

Read more »